<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790279</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00106643</org_study_id>
    <nct_id>NCT04790279</nct_id>
  </id_info>
  <brief_title>Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension</brief_title>
  <official_title>Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: A Randomized Controlled Noninferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prisma Health-Upstate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prisma Health-Upstate</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A significant number of pregnancies are complicated by hypertensive disorders. Hypertension&#xD;
      often worsens in the postpartum period and many women need started on medications. Currently,&#xD;
      recommended medications for blood pressure management in pregnant and postpartum women are&#xD;
      limited, with labetalol and nifedipine ER being the most commonly used medications. While&#xD;
      these medications are both effective, they are not without limitations. Amlodipine is a&#xD;
      medication in the same class as nifedipine ER. It is a first-line antihypertensive in the&#xD;
      general population. It tends to have less side effects than nifedipine ER. It has not been&#xD;
      studied specifically in postpartum women. The purpose of this study is to determine if&#xD;
      amlodipine is noninferior to nifedipine ER in managing hypertension in the postpartum period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Through hospital stay, on average 2-5 days</time_frame>
    <description>length of stay from delivery until discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of additional antihypertensives needed</measure>
    <time_frame>Through hospital stay, on average 2-5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of side effects reported by patient</measure>
    <time_frame>Through hospital stay, on average 2-5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients discontinuing medication due to side effects</measure>
    <time_frame>Through hospital stay, on average 2-5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring hospital readmission</measure>
    <time_frame>until 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding duration</measure>
    <time_frame>until 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients reporting satisfaction with breastfeeding experience on patient-completed questionnaire</measure>
    <time_frame>until 6 weeks postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hypertension in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Initiation of amlodipine 2.5 mg</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIFEdipine ER</intervention_name>
    <description>Initiation of nifedipine ER 30 mg</description>
    <arm_group_label>Nifedipine ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postpartum women with a diagnosis of chronic hypertension, gestational hypertension,&#xD;
             or preeclampsia&#xD;
&#xD;
          -  Delivery at or beyond 20 weeks' gestation&#xD;
&#xD;
          -  Need for antihypertensive therapy, defined as blood pressure &gt;/= 150 mmHg systolic&#xD;
             and/or 100 mmHg diastolic on two occasions four hours apart&#xD;
&#xD;
          -  English or Spanish-speaking&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of antihypertensive prior to delivery (for any indication)&#xD;
&#xD;
          -  Allergy to nifedipine ER or amlodipine&#xD;
&#xD;
          -  Persistent tachycardia (as defined by the treatment team)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Principal Investigator</last_name>
    <phone>864-455-1600</phone>
    <email>katelyn.pratt@prismahealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>864-455-1600</phone>
      <email>katelyn.pratt@prismahealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.</citation>
    <PMID>24150027</PMID>
  </reference>
  <reference>
    <citation>ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):1. doi: 10.1097/AOG.0000000000003018.</citation>
    <PMID>30575675</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019 Jan;133(1):e26-e50. doi: 10.1097/AOG.0000000000003020.</citation>
    <PMID>30575676</PMID>
  </reference>
  <reference>
    <citation>Ainuddin J, Javed F, Kazi S. Oral labetalol versus oral nifedipine for the management of postpartum hypertension a randomized control trial. Pak J Med Sci. 2019 Sep-Oct;35(5):1428-1433. doi: 10.12669/pjms.35.5.812.</citation>
    <PMID>31489020</PMID>
  </reference>
  <reference>
    <citation>Magee L, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004351. doi: 10.1002/14651858.CD004351.pub3. Review.</citation>
    <PMID>23633317</PMID>
  </reference>
  <reference>
    <citation>Cairns AE, Pealing L, Duffy JMN, Roberts N, Tucker KL, Leeson P, MacKillop LH, McManus RJ. Postpartum management of hypertensive disorders of pregnancy: a systematic review. BMJ Open. 2017 Nov 28;7(11):e018696. doi: 10.1136/bmjopen-2017-018696. Review.</citation>
    <PMID>29187414</PMID>
  </reference>
  <reference>
    <citation>Sharma KJ, Greene N, Kilpatrick SJ. Oral labetalol compared to oral nifedipine for postpartum hypertension: A randomized controlled trial. Hypertens Pregnancy. 2017 Feb;36(1):44-47. doi: 10.1080/10641955.2016.1231317. Epub 2016 Oct 27.</citation>
    <PMID>27786578</PMID>
  </reference>
  <reference>
    <citation>8. Bloch, M. (2020). In Basile J. (Ed.), Major side effects and safety of calcium channel blockers. UpToDate.</citation>
  </reference>
  <reference>
    <citation>Hosie J, Bremner AD, Fell PJ, James IG, Saul PA, Taylor SH. Comparison of early side effects with amlodipine and nifedipine retard in hypertension. Cardiology. 1992;80 Suppl 1:54-9.</citation>
    <PMID>1534716</PMID>
  </reference>
  <reference>
    <citation>Naito T, Kubono N, Deguchi S, Sugihara M, Itoh H, Kanayama N, Kawakami J. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding. J Hum Lact. 2015 May;31(2):301-6. doi: 10.1177/0890334414560195. Epub 2014 Dec 1.</citation>
    <PMID>25447596</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

